<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30240" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tolosa-Hunt Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amrutkar</surname>
            <given-names>Chaitanya V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burton</surname>
            <given-names>Erik V.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chaitanya Amrutkar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erik Burton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30240.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tolosa Hunt syndrome (THS), also known as painful ophthalmoplegia, recurrent ophthalmoplegia, or ophthalmoplegia syndrome, is described as severe and unilateral periorbital headaches associated with painful and restricted eye movements. Tolosa Hunt syndrome is one of the rare disorders recognized by the National Organisation for Rare Disorders (NORD). It is also included as one of the painful cranial neuropathies by the International Headache Society in its headache classification. Since its discovery in 1954, many cases of Tolosa Hunt syndrome have been reported. This activity reviews the evaluation and management of Tolosa Hunt syndrome and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the classic presentation of Tolosa Hunt syndrome.</p></list-item><list-item><p>Describe risk factors for the development of Tolosa Hunt syndrome.</p></list-item><list-item><p>Review management strategies for Tolosa Hunt syndrome.</p></list-item><list-item><p>Explain the importance of improving coordination amongst the interprofessional team to enhance the delivery of care for patients affected by Tolosa Hunt syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30240&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30240">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30240.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tolosa Hunt syndrome (THS) is described as severe and unilateral periorbital headache associated with painful and restricted eye movements. Synonyms for Tolosa Hunt syndrome&#x000a0;include painful ophthalmoplegia, recurrent ophthalmoplegia, ophthalmoplegia syndrome. Tolosa Hunt syndrome&#x000a0;is one of the rare disorders recognized by the National Organisation for Rare Disorders (NORD). It is also included as one of the painful cranial neuropathies by the International Headache Society (IHS) in its headache classification. Tolosa Hunt syndrome&#x000a0;was first described in the year 1954 by Dr. Eduardo&#x000a0;Tolosa, a Spanish neurosurgeon.<xref ref-type="bibr" rid="article-30240.r1">[1]</xref> Similar cases were reported by Hunt et al. in 1961.<xref ref-type="bibr" rid="article-30240.r2">[2]</xref> Smith and Taxdal called it Tolosa Hunt Syndrome for the first time&#x000a0;in 1966.<xref ref-type="bibr" rid="article-30240.r3">[3]</xref> Until then, it was then an obscure clinical entity. Since then, numerous cases and studies have been reported around the world.</p>
      </sec>
      <sec id="article-30240.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Tolosa Hunt syndrome is usually idiopathic and is thought to be from non-specific inflammation in the region of the cavernous sinus and/or superior orbital fissure. However, traumatic injury, tumors, or an&#x000a0;aneurysm could be the potential triggers.&#x000a0;</p>
      </sec>
      <sec id="article-30240.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The annual estimated incidence of Tolosa Hunt syndrome&#x000a0;is about one case per million per year.<xref ref-type="bibr" rid="article-30240.r4">[4]</xref> It is found worldwide without any geographical or racial preponderance. It is unusual to see Tolosa Hunt syndrome&#x000a0;in young people. The average age of onset is 41 years according to the National Organization for Rare Disorder. Although usually unilateral, either side can be affected, and there have been case reports about bilateral involvement (approximately 5%). There is no male-female predisposition.<xref ref-type="bibr" rid="article-30240.r5">[5]</xref></p>
      </sec>
      <sec id="article-30240.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>As mentioned before, Tolosa Hunt syndrome is caused by non-specific inflammation of unknown etiology. In his initial report, Dr. Eduardo Tolosa described the pathophysiology as "non-specific, chronic inflammation of the septa and wall of the cavernous sinus with the proliferation of fibroblasts an infiltration with lymphocytes and plasma cells."<xref ref-type="bibr" rid="article-30240.r1">[1]</xref> Hunt et al. not only agreed with above observation but also added that "such inflammatory changes, in a tight connective tissue, may exert pressure upon the penetrating nerves."<xref ref-type="bibr" rid="article-30240.r2">[2]</xref> These nerves can be cranial nerves III, IV, VI, as well as the superior division of the fifth cranial nerve. Further studies showed the presence of granulomatous material deposits along with epitheloid cells and giant cells. Occasionally necrosis has been seen, but it is rare. There is also associated thickening of dura mater within the cavernous sinus.</p>
        <p>The inflammation in the cavernous sinus region has seen a rare association with intracranial inflammation, but systemic inflammation is not yet reported.<xref ref-type="bibr" rid="article-30240.r4">[4]</xref> Although there has not been a clear autoimmune etiology associated with Tolosa Hunt syndrome, it has been reported with other systemic and autoimmune inflammatory disorders such as systemic lupus erythematosus, sarcoidosis, and Wegener's granulomatosis and could be a presenting complaint of these diseases.<xref ref-type="bibr" rid="article-30240.r6">[6]</xref><xref ref-type="bibr" rid="article-30240.r7">[7]</xref>&#x000a0;There does not seem to be any association with any infectious agent.</p>
      </sec>
      <sec id="article-30240.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The hallmark of this syndrome is a pain, which can be described as sharp, shooting, stabbing, boring, severe, and intense. Pain is usually located in the periorbital region but can often be retro-orbital, with extension into the frontal and temporal areas. Pain tends to be&#x000a0;the presenting symptom and can precede ophthalmoplegia by up to 30 days. Tolosa Hunt syndrome&#x000a0;tends to have a relapsing and remitting course, with attacks recurring every few months or years. Other associated features include involvement of all three ocular motor nerves (which include oculomotor, trochlear, abducens nerves) in different combinations, leading to ophthalmoplegia. Ophthalmic branch of the trigeminal nerve is commonly affected.&#x000a0;The oculomotor nerve is most commonly involved (approximately 80%), followed by abducens nerve (approximately&#x000a0;70%), an ophthalmic branch of trigeminal nerve (approximately&#x000a0;30%), and trochlear nerve (approximately&#x000a0;29%).<xref ref-type="bibr" rid="article-30240.r4">[4]</xref>&#x000a0;There can also be sympathetic (third order neuron Horner syndrome, in&#x000a0;approximately&#x000a0;20% cases) or parasympathetic (oculomotor) involvement which leads to pupillary abnormalities.<xref ref-type="bibr" rid="article-30240.r8">[8]</xref><xref ref-type="bibr" rid="article-30240.r9">[9]</xref> There are reports of involvement of the maxillary and mandibular divisions of the fifth cranial nerve (trigeminal), optic nerve, and facial nerve which suggest an extension of the disease process beyond the cavernous sinus.<xref ref-type="bibr" rid="article-30240.r3">[3]</xref><xref ref-type="bibr" rid="article-30240.r2">[2]</xref><xref ref-type="bibr" rid="article-30240.r10">[10]</xref><xref ref-type="bibr" rid="article-30240.r11">[11]</xref><xref ref-type="bibr" rid="article-30240.r12">[12]</xref>&#x000a0;Rarely, inflammation can involve orbital apex leading to optic nerve damage and consequent optic disc pallor or swelling. Loss of visual acuity in those cases is unpredictable and can be permanent.<xref ref-type="bibr" rid="article-30240.r13">[13]</xref></p>
        <p>Tolosa Hunt syndrome usually does not have any other neurological or systemic involvement.<xref ref-type="bibr" rid="article-30240.r4">[4]</xref> Some studies report nausea and vomiting, which are probably a result of the intense pain the patient experiences and tend to resolve with pain control. Chronic fatigue is reported. Symptoms of Tolosa Hunt syndrome&#x000a0;can last up to eight weeks if not treated and then resolve spontaneously. There are seldom any residual neurological deficits.&#x000a0;<xref ref-type="bibr" rid="article-30240.r14">[14]</xref></p>
      </sec>
      <sec id="article-30240.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Tolosa Hunt syndrome is diagnosed through the clinical presentation, neuroimaging studies, and response to steroids. Laboratory tests and cerebrospinal fluid (CSF) studies are supportive tests but help in ruling out other causes of ophthalmoplegia. Tissue biopsy is diagnostic but is considered the procedure of the last choice and rarely performed, given high risk and technical difficulties.</p>
        <p>
<bold>International Headache Society (IHS) Diagnostic Criteria</bold>
</p>
        <p>Tolosa Hunt Syndrome also finds&#x000a0;a place in the IHS Classification ICHD-3 Beta, in part three, under Painful cranial neuropathies and other facial pains. The IHS lays down diagnostic criteria for THS which have high sensitivity (approximately&#x000a0;95% to 100%) but low specificity (approximately&#x000a0;50%).<xref ref-type="bibr" rid="article-30240.r15">[15]</xref>&#x000a0;They are summarized as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Unilateral headache</p>
          </list-item>
          <list-item>
            <p>Includes both of the following:</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Presence of granulomatous inflammation of the cavernous sinus, superior orbital fissure or orbit, as seen on MRI or biopsy</p>
          </list-item>
          <list-item>
            <p>Palsies of one or more of the oculomotor nerves (cranial nerves III, IV, and/or VI) on the same side</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Corroboration of the cause as evidenced by&#x000a0;both of the following:</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Palsies of cranial nerves III, IV, and/or VI have followed headache in two weeks or less, or have developed simultaneously with a headache</p>
          </list-item>
          <list-item>
            <p>Localization of a headache around the eye on the same side</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Not better explained by any other headache etiology</p>
          </list-item>
        </list>
        <p>
<bold>Neuroimaging</bold>
</p>
        <p>MRI brain with contrast, especially the coronal view, is a crucial diagnostic study. It helps exclude other disease processes that produce painful ophthalmoplegia as it is rarely normal in cases of Tolosa Hunt syndrome. MRI can show thickening of the cavernous sinus because of the presence of abnormal soft tissue which is isointense on T1, iso or hypointense on T2, and enhances with contrast. Other MRI findings include convexity of the lateral wall of the cavernous sinus, extension into the orbital apex.&#x000a0;High-resolution computed tomography (HRCT) can also show changes in the soft tissue, but lacks sensitivity.&#x000a0;Thus, MRI should be performed for better visualization of the region of the cavernous sinus and/or superior orbital fissure. MRI findings have low specificity, and above-mentioned findings can also be found in lymphoma, meningioma, and sarcoidosis.<xref ref-type="bibr" rid="article-30240.r5">[5]</xref> There are reports of vascular abnormalities in the intracavernous segment of carotid artery which show segmental narrowing, constriction, irregularities. These changes can be detected by MR angiography, CT angiography, digital subtraction angiography and usually resolve with steroids.</p>
        <p>
<bold>Other Tests</bold>
</p>
        <p>When there is suspicion of&#x000a0;Tolosa Hunt syndrome&#x000a0;on clinical presentation and MRI, blood and CSF studies should be performed to rule out other causes of painful ophthalmoplegia (see Other Issues at the end of discussion); as Tolosa Hunt syndrome&#x000a0;remains a clinical diagnosis of exclusion.<xref ref-type="bibr" rid="article-30240.r5">[5]</xref> Blood tests include Complete Blood Count, Comprehensive Metabolic Panel, HbA1C, Erythrocyte Sedimentation Rate, C Reactive Protein, Angiotensin Converting Enzyme, Anti-nuclear Antibody, Anti-nuclear Cytoplasmic Antibody, Anti-dsDNA Antibody, Anti-sm Antibody, Lyme Panel, Serum Protein Electrophoresis, Fluorescent Treponemal Antibody Test. CSF studies include glucose, protein, cell count and differential, cytology, culture and gram stain, angiotensin converting enzyme, syphilis and Lyme serology. Blood, as well as CSF studies, are expected to be normal in cases of Tolosa Hunt syndrome. If there are abnormalities found, another diagnosis should be considered.</p>
        <p>
<bold>Glucocorticoid Response</bold>
</p>
        <p>Glucocorticoid response finds mention here as it helps with diagnosis as well as treatment. Treating with high doses of systemic steroids leads to a dramatic improvement in pain within two to three days. Cranial nerve dysfunction improves, and&#x000a0;there is a reduction in abnormal tissue volume as well as signal intensity on MRI over the next few weeks of steroid treatment.<xref ref-type="bibr" rid="article-30240.r8">[8]</xref>&#x000a0;Reduction in pain&#x000a0;helps confirm the diagnosis and is further supported by cranial nerve dysfunction improvement and resolution of MRI findings.&#x000a0;However, caution should be taken when confirming the diagnosis of Tolosa Hunt syndrome&#x000a0;with steroid response as improvement clinically as well as radiologically is known to occur with other disease processes such as malignancies, infection, or vasculitis.<xref ref-type="bibr" rid="article-30240.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30240.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Glucocorticoids have been the mainstay of the treatment ever since the syndrome was first described.<xref ref-type="bibr" rid="article-30240.r2">[2]</xref><xref ref-type="bibr" rid="article-30240.r3">[3]</xref> But there is no specific data to give recommendations about dose, duration, or route of administration.<xref ref-type="bibr" rid="article-30240.r5">[5]</xref> Spontaneous remission of symptoms is known to occur. Although orbital pain drastically improves with steroid treatment, there is no evidence to suggest cranial nerve palsies improve faster with it. As with any glucocorticoid regimen, treatment for Tolosa Hunt syndrome&#x000a0;involves initial high-dose therapy for few days followed by a gradual taper over weeks to months.<xref ref-type="bibr" rid="article-30240.r16">[16]</xref> Symptom resolution guides the degree and rapidity of the taper.&#x000a0;Imaging studies like MRI can be repeated for follow-up, but usually, lag behind a few weeks as compared to symptomatic improvement.&#x000a0;</p>
        <p>A very small percentage of patients will require immunosuppression with other agents, either to avoid side effects of long-term steroid therapy or for long-term suppression of the disease process itself. Azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, and infliximab have been used as second-line therapy.&#x000a0;There have been reports of radiotherapy being used as second-line therapy for recurrent flare-ups leading to steroid dependence or as a first-line therapy in the presence of contraindications to steroids.&#x000a0;Usually, these patients would have had a biopsy-proven diagnosis of Tolosa Hunt syndrome, before a second-line therapy is initiated.&#x000a0;<xref ref-type="bibr" rid="article-30240.r17">[17]</xref></p>
        <p><bold>Prognosis:</bold>&#x000a0;Tolosa Hunt Syndrome is characterized by the dramatic symptomatic improvement seen with Glucocorticoids. Symptom improvement, especially pain relief, is usually seen 24 to 72 hours after starting steroids, with the majority of patients reporting improvement within one week. Cranial nerve palsies improve gradually and can take anywhere from two to eight weeks for recovery.<xref ref-type="bibr" rid="article-30240.r3">[3]</xref>&#x000a0;It is unusual to have residual deficits after steroid treatment.&#x000a0;</p>
        <p>Relapses tend to occur in about 40% to 50% of patients and can be ipsilateral, contralateral, or bilateral.<xref ref-type="bibr" rid="article-30240.r2">[2]</xref> Relapses are more common in younger patients than&#x000a0;in older patients. Every relapse should ideally be investigated with a full work up as Tolosa Hunt syndrome&#x000a0;is a diagnosis of exclusion.<xref ref-type="bibr" rid="article-30240.r12">[12]</xref>&#x000a0;It is unclear as to whether steroids help prevent relapses.&#x000a0;<xref ref-type="bibr" rid="article-30240.r18">[18]</xref></p>
      </sec>
      <sec id="article-30240.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Anisocoria</p>
          </list-item>
          <list-item>
            <p>Benign Skull Tumors</p>
          </list-item>
          <list-item>
            <p>Brain Mets</p>
          </list-item>
          <list-item>
            <p>Cavernous Sinus Syndromes</p>
          </list-item>
          <list-item>
            <p>Cerebral Aneurysms</p>
          </list-item>
          <list-item>
            <p>Cerebral Venous Thrombosis</p>
          </list-item>
          <list-item>
            <p>CNS Whipple Disease</p>
          </list-item>
          <list-item>
            <p>Diabetic Neuropathy</p>
          </list-item>
          <list-item>
            <p>Epidural Hematoma</p>
          </list-item>
          <list-item>
            <p>Lyme Disease</p>
          </list-item>
          <list-item>
            <p>Meningioma</p>
          </list-item>
          <list-item>
            <p>Migraine Headache</p>
          </list-item>
          <list-item>
            <p>Neurosarcoidosis</p>
          </list-item>
          <list-item>
            <p>Pediatric Craniopharyngioma</p>
          </list-item>
          <list-item>
            <p>Polyarteritis Nodosa</p>
          </list-item>
          <list-item>
            <p>Primary CNS Lymphoma</p>
          </list-item>
          <list-item>
            <p>Primary Malignant Skull Tumors</p>
          </list-item>
          <list-item>
            <p>Systemic Lupus Erythematosus</p>
          </list-item>
          <list-item>
            <p>Tuberculous Meningitis</p>
          </list-item>
          <list-item>
            <p>Varicella Zoster</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30240.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Since it is very rare, the majority of patients who present with painful ophthalmoplegia will not have Tolosa Hunt syndrome. Painful ophthalmoplegia is essentially a result of a mass effect produced in the cavernous sinus which can be caused by many disease processes. Tolosa Hunt syndrome&#x000a0;is ultimately a diagnosis of exclusion, and thus, clinicians should be aware of the differential diagnoses. Various causes of painful ophthalmoplegia include the following:</p>
        <p>
<bold>Trauma</bold>
</p>
        <p>
<bold>Vascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intracavernous carotid artery aneurysm</p>
          </list-item>
          <list-item>
            <p>Posterior cerebral artery aneurysm</p>
          </list-item>
          <list-item>
            <p>Carotid-cavernous fistula</p>
          </list-item>
          <list-item>
            <p>Carotid-cavernous thrombosis</p>
          </list-item>
          <list-item>
            <p>Posterior communicating artery aneurysm</p>
          </list-item>
          <list-item>
            <p>Basilar artery aneurysm</p>
          </list-item>
          <list-item>
            <p>Internal carotid artery dissection</p>
          </list-item>
        </list>
        <p>
<bold>Neoplasm</bold>
</p>
        <p>
<italic toggle="yes">Primary intracranial tumor</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pituitary adenoma</p>
          </list-item>
          <list-item>
            <p>Meningioma</p>
          </list-item>
          <list-item>
            <p>Craniopharyngioma, others</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Primary cranial tumor</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chordoma, others</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Local metastases</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngeal tumour</p>
          </list-item>
          <list-item>
            <p>Squamous cell carcinoma</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Distant metastases</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Carcinomatous metastases</p>
          </list-item>
        </list>
        <p>
<bold>Inflammation, infection</bold>
</p>
        <p>
<italic toggle="yes">Bacterial</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Contiguous sinusitis</p>
          </list-item>
          <list-item>
            <p>Mucocele (sphenoid sinus)</p>
          </list-item>
          <list-item>
            <p>Periostitis</p>
          </list-item>
          <list-item>
            <p>Abscess</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Viral</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Herpes zoster</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Fungal</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mucormycosis, Actinomycosis</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Spirochetal</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treponema pallidum</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Mycobacterial</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mycobacterium tuberculosis</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Others</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Wegener's granulomatosis</p>
          </list-item>
          <list-item>
            <p>Eosinophilic granuloma</p>
          </list-item>
          <list-item>
            <p>Tolosa-Hunt syndrome</p>
          </list-item>
          <list-item>
            <p>Orbital pseudotumor</p>
          </list-item>
        </list>
        <p>
<bold>Miscellaneous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic ophthalmoplegia</p>
          </list-item>
          <list-item>
            <p>Ophthalmoplegic migraine</p>
          </list-item>
          <list-item>
            <p>Giant cell arteritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30240.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The primary care provider, nurse practitioner, and internist will often encounter patients with a headache. However, when they encounter a patient with an intense headache and ophthalmoplegia, a referral to a neurologist is necessary. Unlike the typical headache, patients with the Tolosa Hunt syndrome are managed with steroids and immunosuppressive agents. Despite treatment, recurrences are common and the overally quality of life is poor. When patients are managed with steroids, the nurse practitioner and primary care giver should monitor the patient for adverse effects. An interprofessional approach to the care of this disease will provide the best patient outcome. [Level V]</p>
      </sec>
      <sec id="article-30240.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30240&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30240">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/tolosa-hunt-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30240">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30240/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30240">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30240.s13">
        <fig id="article-30240.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Coronal T1 with contrast on MRI Brain in Tolosa-Hunt Syndrome Contributed by Chaitanya Amrutkar, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Coronal__T1__sequence__with__contrast" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30240.s14">
        <fig id="article-30240.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Axial FSPGR sequence with contrast on MRI in Tolosa-Hunt Syndrome Contributed by Chaitanya Amrutkar, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Axial__FSPGR__sequence__with__contrast" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30240.s15">
        <title>References</title>
        <ref id="article-30240.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>TOLOSA</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1954</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-2</page-range>
            <pub-id pub-id-type="pmid">13212421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HUNT</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>MEAGHER</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>LEFEVER</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>ZEMAN</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Painful opthalmoplegia. Its relation to indolent inflammation of the carvernous sinus.</article-title>
            <source>Neurology</source>
            <year>1961</year>
            <month>Jan</month>
            <volume>11</volume>
            <fpage>56</fpage>
            <page-range>56-62</page-range>
            <pub-id pub-id-type="pmid">13716871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Taxdal</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Painful ophthalmoplegia. The Tolosa-Hunt syndrome.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1966</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>1466</fpage>
            <page-range>1466-72</page-range>
            <pub-id pub-id-type="pmid">5938314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iaconetta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cappabianca</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tolosa-Hunt syndrome extending in the cerebello-pontine angle.</article-title>
            <source>Cephalalgia</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>746</fpage>
            <page-range>746-50</page-range>
            <pub-id pub-id-type="pmid">16109058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kline</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Hoyt</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>The Tolosa-Hunt syndrome.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>577</fpage>
            <page-range>577-82</page-range>
            <pub-id pub-id-type="pmid">11606665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calistri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mostardini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pantano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pierallini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colonnese</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caramia</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Tolosa-Hunt syndrome in a patient with systemic lupus erythematosus.</article-title>
            <source>Eur Radiol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-4</page-range>
            <pub-id pub-id-type="pmid">11870431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trobe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hood</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Quisling</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Intracranial spread of squamous carcinoma along the trigeminal nerve.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>608</fpage>
            <page-range>608-11</page-range>
            <pub-id pub-id-type="pmid">7073576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cakirer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>MRI findings in Tolosa-Hunt syndrome before and after systemic corticosteroid therapy.</article-title>
            <source>Eur J Radiol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">12536085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Arcaya</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cerezal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Canga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Berciano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging diagnosis of Tolosa-Hunt syndrome: MRI contribution.</article-title>
            <source>Headache</source>
            <year>1999</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>321</fpage>
            <page-range>321-5</page-range>
            <pub-id pub-id-type="pmid">11279911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tessitore</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tessitore</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tolosa-Hunt syndrome preceded by facial palsy.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>393</fpage>
            <page-range>393-6</page-range>
            <pub-id pub-id-type="pmid">10849035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sondheimer</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Angiographic findings in the Tolosa-Hunt syndrome: painful ophthalmoplegia.</article-title>
            <source>Radiology</source>
            <year>1973</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <page-range>105-12</page-range>
            <pub-id pub-id-type="pmid">4682706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>F&#x000f6;rderreuther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The criteria of the International Headache Society for Tolosa-Hunt syndrome need to be revised.</article-title>
            <source>J Neurol</source>
            <year>1999</year>
            <month>May</month>
            <volume>246</volume>
            <issue>5</issue>
            <fpage>371</fpage>
            <page-range>371-7</page-range>
            <pub-id pub-id-type="pmid">10399869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaye</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Craciun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tubbs</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Intracranial extension of inflammatory pseudotumor of the orbit. Case report.</article-title>
            <source>J Neurosurg</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>625</fpage>
            <page-range>625-9</page-range>
            <pub-id pub-id-type="pmid">6699710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsirigotaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ntoulios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lioumpas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voutoufianakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vorgia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tolosa-Hunt Syndrome: Clinical Manifestations in Children.</article-title>
            <source>Pediatr Neurol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>99</volume>
            <fpage>60</fpage>
            <page-range>60-63</page-range>
            <pub-id pub-id-type="pmid">30982655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
            <article-title>The International Classification of Headache Disorders, 3rd edition (beta version).</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>629</fpage>
            <page-range>629-808</page-range>
            <pub-id pub-id-type="pmid">23771276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Progression of Tolosa-Hunt syndrome to a cavernous dural arteriovenous fistula: a case report.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-6</page-range>
            <pub-id pub-id-type="pmid">12558766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rutland</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Bederson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrivastava</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Reappraising the Tolosa-Hunt Syndrome Diagnostic Criteria: A Case Series.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>259</fpage>
            <page-range>259-264</page-range>
            <pub-id pub-id-type="pmid">31681980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30240.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiener</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cron</surname>
                <given-names>RQ</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of pediatric Tolosa-Hunt syndrome with adalimumab.</article-title>
            <source>Eur J Rheumatol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>Suppl1</issue>
            <fpage>S82</fpage>
            <page-range>S82-S84</page-range>
            <pub-id pub-id-type="pmid">31804175</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
